144 related articles for article (PubMed ID: 20010957)
1. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.
Bauer M; Karch R; Neumann F; Wagner CC; Kletter K; Müller M; Löscher W; Zeitlinger M; Langer O
J Cereb Blood Flow Metab; 2010 Mar; 30(3):510-5. PubMed ID: 20010957
[TBL] [Abstract][Full Text] [Related]
2. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
3. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
[TBL] [Abstract][Full Text] [Related]
4. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
5. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
[TBL] [Abstract][Full Text] [Related]
6. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
7. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.
Bauer M; Zeitlinger M; Karch R; Matzneller P; Stanek J; Jäger W; Böhmdorfer M; Wadsak W; Mitterhauser M; Bankstahl JP; Löscher W; Koepp M; Kuntner C; Müller M; Langer O
Clin Pharmacol Ther; 2012 Feb; 91(2):227-33. PubMed ID: 22166851
[TBL] [Abstract][Full Text] [Related]
8. A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier.
Bankstahl JP; Bankstahl M; Kuntner C; Stanek J; Wanek T; Meier M; Ding XQ; Müller M; Langer O; Löscher W
J Neurosci; 2011 Jun; 31(24):8803-11. PubMed ID: 21677164
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil.
Langer O; Bauer M; Hammers A; Karch R; Pataraia E; Koepp MJ; Abrahim A; Luurtsema G; Brunner M; Sunder-Plassmann R; Zimprich F; Joukhadar C; Gentzsch S; Dudczak R; Kletter K; Müller M; Baumgartner C
Epilepsia; 2007 Sep; 48(9):1774-1784. PubMed ID: 17484754
[TBL] [Abstract][Full Text] [Related]
12. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET.
Bauer M; Karch R; Neumann F; Abrahim A; Wagner CC; Kletter K; Müller M; Zeitlinger M; Langer O
Eur J Clin Pharmacol; 2009 Sep; 65(9):941-6. PubMed ID: 19655132
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
[TBL] [Abstract][Full Text] [Related]
14. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
[TBL] [Abstract][Full Text] [Related]
15. Age dependency of cerebral P-glycoprotein function in wild-type and APPPS1 mice measured with PET.
Zoufal V; Wanek T; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Bauer M; Pahnke J; Langer O
J Cereb Blood Flow Metab; 2020 Jan; 40(1):150-162. PubMed ID: 30354871
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study.
Feldmann M; Asselin MC; Liu J; Wang S; McMahon A; Anton-Rodriguez J; Walker M; Symms M; Brown G; Hinz R; Matthews J; Bauer M; Langer O; Thom M; Jones T; Vollmar C; Duncan JS; Sisodiya SM; Koepp MJ
Lancet Neurol; 2013 Aug; 12(8):777-85. PubMed ID: 23786896
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)-[
Ilyas-Feldmann M; Asselin MC; Wang S; McMahon A; Anton-Rodriguez J; Brown G; Hinz R; Duncan JS; Sisodiya SM; Koepp M
Epilepsia; 2020 Jul; 61(7):1472-1480. PubMed ID: 32627849
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
Kannan P; Brimacombe KR; Kreisl WC; Liow JS; Zoghbi SS; Telu S; Zhang Y; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2593-8. PubMed ID: 21262843
[TBL] [Abstract][Full Text] [Related]
19. Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET.
Syvänen S; Labots M; Tagawa Y; Eriksson J; Windhorst AD; Lammertsma AA; de Lange EC; Voskuyl RA
J Nucl Med; 2012 Dec; 53(12):1974-83. PubMed ID: 23143088
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress.
Thoeringer CK; Wultsch T; Shahbazian A; Painsipp E; Holzer P
Psychoneuroendocrinology; 2007; 32(8-10):1028-40. PubMed ID: 17881135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
